Bill Text: TX SB1838 | 2023-2024 | 88th Legislature | Introduced
Bill Title: Relating to the creation of the Alzheimer's Research Collaborative of Texas.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2023-03-20 - Referred to Health & Human Services [SB1838 Detail]
Download: Texas-2023-SB1838-Introduced.html
2023S0230-2 03/02/23 | ||
By: Hinojosa | S.B. No. 1838 |
|
||
|
||
relating to the creation of the Alzheimer's Research Collaborative | ||
of Texas. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Subchapter D, Chapter 102, Health and Safety | ||
Code, is amended by adding Section 102.157 to read as follows: | ||
Sec. 102.157. OVERSIGHT COMMITTEE FOR NEURODEGENERATIVE | ||
DISEASES. (a) In this section: | ||
(1) "Committee" means the Oversight Committee for | ||
Neurodegenerative Diseases. | ||
(2) "Nationally designated" means a designation from | ||
the National Institute on Aging. | ||
(3) "Research collaborative" means the Alzheimer's | ||
Research Collaborative of Texas. | ||
(b) The Oversight Committee for Neurodegenerative Diseases | ||
is the governing body of the Alzheimer's Research Collaborative of | ||
Texas. The committee is composed of the following eight members: | ||
(1) four members appointed by the lieutenant governor; | ||
and | ||
(2) four members appointed by the speaker of the house | ||
of representatives. | ||
(c) In making appointments to the committee, the lieutenant | ||
governor and the speaker of the house of representatives must each | ||
appoint: | ||
(1) three members who are physicians or scientists | ||
with extensive experience in the field of Alzheimer's disease and | ||
neurology; and | ||
(2) one member of the public. | ||
(d) From each group of appointees under Subsection (c)(1), | ||
one appointee must represent a nationally designated Alzheimer's | ||
Disease Research Center and shall serve as co-chair of the | ||
committee. | ||
(e) A member of the committee serves at the will of the | ||
official who appointed the member. | ||
(f) The research collaborative is established to support | ||
Alzheimer's disease research described by Subsection (h). The | ||
committee shall oversee the review processes and related procedures | ||
of the collaborative. | ||
(g) The committee shall establish standards and hire | ||
personnel as necessary to ensure the proper use of funds authorized | ||
for Alzheimer's disease research, facilities development, and | ||
caregiver resources consistent with the powers and duties described | ||
under Section 102.051. | ||
(h) The committee shall establish criteria for the research | ||
collaborative to support institutions of learning and advanced | ||
medical research facilities and collaborations in this state in all | ||
stages of finding the causes of Alzheimer's disease and other | ||
neurodegenerative diseases in humans and developing cures, from | ||
laboratory research to clinical trials, including programs to | ||
address the problem of access to advanced treatment for Alzheimer's | ||
disease. | ||
(i) The committee shall establish criteria for prioritizing | ||
its review of applications for grants to: | ||
(1) academic medical centers; | ||
(2) medical research facilities; and | ||
(3) collaborations with a nationally designated | ||
Alzheimer's Disease Research Center. | ||
SECTION 2. This Act takes effect September 1, 2023. |